Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Fertility and Sterility

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.fertnstert.2009.05.044PMID 19591981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.

  2008cited by this paper
• Review of the combined contraceptive vaginal ring, NuvaRing®

  2008cited by this paper
• Vascular Risk in Young Women With Polycystic Ovary and Polycystic Ovary Syndrome

  2008cited by this paper
• Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

  2006cited by this paper
• Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance

  2006cited by this paper
• Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.

  2005cited by this paper
• Decreased nitric oxide in women with essential hypertension in prehypertensive phase.

  2005cited by this paper
• The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

  2005cited by this paper
• Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.

  2005cited by this paper
• Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects.

  2005cited by this paper
• Drospirenone in combination with estrogens: for contraception and hormone replacement therapy

  2005cited by this paper
• Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.

  2004cited by this paper
• Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.

  2004cited by this paper
• An observational study of Yasmin® in the management of women with polycystic ovary syndrome

  2004cited by this paper
• A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.

  2003cited by this paper
• Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.

  2003cited by this paper
• Polycystic ovary syndrome and cardiovascular disease: a premature association?

  2003cited by this paper
• A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.

  2003cited by this paper
• Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.

  2002cited by this paper
• Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: a double-blind, randomized study.

  2002cited by this paper
• Diurnal variation of flow-mediated vasodilation in healthy premenopausal women.

  2000cited by this paper
• The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long‐term oestrogen–progestagen treatment

  1999cited by this paper
• Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome

  1998cited by this paper
• Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations

  1998cited by this paper
• Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

  1997cited by this paper
• The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.

  1997cited by this paper
• Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study

  1997cited by this paper
• EFFECTS OF TRANSDERMAL GLYCERYLTRINITRATE ON 24-H BLOOD PRESSURE CHANGES IN PATIENTS WITH GESTATIONAL HYPERTENSION

  1996cited by this paper
• Circadian variation in uterine artery blood flow indices during the follicular phase of the menstrual cycle

  1995cited by this paper
• A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth International Consensus Conference on 24-Hour Ambulatory Blood Pressure Monitoring.

  1995cited by this paper
• The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome.

  1995cited by this paper
• Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.

  1995cited by this paper
• Evaluation of WHO and NDDG criteria for impaired glucose tolerance.

  1994cited by this paper
• Nitric oxide: physiology, pathophysiology, and pharmacology.

  1991cited by this paper
• The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

  1990cited by this paper
• Flow-mediated and reflex changes in large peripheral artery tone in humans.

  1989cited by this paper
• Evaluation of WHO and NDDG Criteria for Impaired Glucose Tolerance: Results From Two National Samples

  1989cited by this paper
• Clinical assessment of body hair growth in women.

  1961cited by this paper

• Basics of counseling when prescribing vaginal contraceptive rings with ethinyl estradiol and etonogestrel: A review

  2025cites this paper
• Oral and Vaginal Hormonal Contraceptives Induce Similar Unfavorable Metabolic Effects in Women with PCOS: A Randomized Controlled Trial

  2023cites this paper
• Combined oral contraceptives: Why, when, where?

  2022cites this paper
• The effect of non‐oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta‐analysis

  2022influential citation
• Variations in the Profiles of Vascular-Related Factors Among Different Sub-Types of Polycystic Ovarian Syndrome in Northern China

  2021cites this paper
• Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study

  2020cites this paper
• Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis

  2020cites this paper
• A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy

  2020cites this paper
• Hormonal Contraceptives and Dermatology

  2020cites this paper
• Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis

  2019cites this paper
• Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study

  2019cites this paper
• Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee Opinion, Number 789.

  2019cites this paper
• Treatments

  2018cites this paper
• Odabir hormonske kontracepcije ovisno o fenotipu sindroma policističnih jajnika

  2018influential citation
• Клинико-анамнестические, иммунологические, эхографические и гистероскопические особенности хронического эндометрита, ассоциированного с нарушением репродуктивной функции

  2018cites this paper
• No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception.

  2017cites this paper
• Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

  2017influential citation
• An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence

  2017cites this paper
• Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits

  2017cites this paper
• Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A prospective pilot study

  2017cites this paper
• Non-Contraceptive Benefits of Hormonal Contraception: Established Benefits and New Findings

  2017cites this paper
• No 329-Consensus canadien sur la contraception (4e partie de 4) : chapitre 9 – contraception hormonale combinée

  2017cites this paper
• Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

  2017cites this paper
• Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome

  2016cites this paper
• The Combined Contraceptive Vaginal Ring: an Update

  2016cites this paper
• Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments

  2016cites this paper
• Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits.

  2016cites this paper
• Targets to treat androgen excess in polycystic ovary syndrome

  2015cites this paper
• Effects of two contraceptives containing drospirenone on blood pressure in normotensive women: a randomized-controlled trial

  2015cites this paper
• Nuevas recomendaciones para el consejo anticonceptivo basadas en el estilo de vida. Resultados de un estudio Delphi

  2015cites this paper
• Interventions for hirsutism (excluding laser and photoepilation therapy alone).

  2015cites this paper
• Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women.

  2014cites this paper
• The effect of drospirenone (3 mg) with ethinyl estradiol (30 mcg) containing pills on ovarian blood flows in women with polycystic ovary syndrome: a case controlled study.

  2014influential citation
• Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients.

  2014cites this paper
• Contraception for Women with Endocrine Abnormalities

  2014cites this paper
• Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use

  2014cites this paper
• Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies

  2014cites this paper
• Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study.

  2014cites this paper
• Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study.

  2013cites this paper
• Cigarette Smoking and Cardiovascular Risk in Young Women with Polycystic Ovary Syndrome

  2013cites this paper
• Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: a prospective study.

  2013cites this paper
• Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome

  2013cites this paper
• Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.

  2012cites this paper
• Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?

  2012cites this paper
• Polycystic ovary syndrome: a common but often unrecognized condition.

  2012cites this paper
• ORIGINAL RESEARCH—WOMEN'S SEXUAL HEALTH

  2012cites this paper
• Sexual behavior and oral contraception: a pilot study.

  2012cites this paper
• The Polycystic Ovary Syndrome Status - A Risk Factor for Future Cardiovascular Disease

  2012cites this paper
• [The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome].

  2011cites this paper
• Vaginal ring contraception.

  2011cites this paper
• MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome

  2011cites this paper
• Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate

  2011cites this paper
• Ovarian hypertension: polycystic ovary syndrome.

  2011cites this paper
• Therapieoptionen bei polyzystischem Ovarsyndrom mit oder ohne Kinderwunsch

  2011cites this paper
• Surgical Management Options for Patients with Infertility and Endometriosis

  2010cites this paper